Literature DB >> 30765470

Durable remissions in TCF3-HLF positive acute lymphoblastic leukemia with blinatumomab and stem cell transplantation.

Brice Mouttet1, Luciana Vinti2, Philip Ancliff3, Nicole Bodmer1, Benoît Brethon4, Gunnar Cario5, Christiane Chen-Santel6, Sarah Elitzur7, Volkan Hazar8, Joachim Kunz9, Anja Möricke5, Jerry Stein10, Ajay Vora3, Yöntem Yaman8, Martin Schrappe5,11, Sema Anak8, André Baruche1,4, Franco Locatelli2, Arend von Stackelberg6, Martin Stanulla12, Jean-Pierre Bourquin13.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30765470      PMCID: PMC6545832          DOI: 10.3324/haematol.2018.210104

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  14 in total

1.  BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents.

Authors:  Jing Deng; Nicole Carlson; Kunihiko Takeyama; Paola Dal Cin; Margaret Shipp; Anthony Letai
Journal:  Cancer Cell       Date:  2007-08       Impact factor: 31.743

2.  Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.

Authors:  Max S Topp; Peter Kufer; Nicola Gökbuget; Mariele Goebeler; Matthias Klinger; Svenja Neumann; Heinz-A Horst; Thorsten Raff; Andreas Viardot; Mathias Schmid; Matthias Stelljes; Markus Schaich; Evelyn Degenhard; Rudolf Köhne-Volland; Monika Brüggemann; Oliver Ottmann; Heike Pfeifer; Thomas Burmeister; Dirk Nagorsen; Margit Schmidt; Ralf Lutterbuese; Carsten Reinhardt; Patrick A Baeuerle; Michael Kneba; Hermann Einsele; Gert Riethmüller; Dieter Hoelzer; Gerhard Zugmaier; Ralf C Bargou
Journal:  J Clin Oncol       Date:  2011-05-16       Impact factor: 44.544

3.  Accelerating drug development in pediatric cancer: a novel Phase I study design of venetoclax in relapsed/refractory malignancies.

Authors:  Andrew E Place; Kelly Goldsmith; Jean-Pierre Bourquin; Mignon L Loh; Lia Gore; Daniel A Morgenstern; Yeshwant Sanzgiri; David Hoffman; Ying Zhou; Jeremy A Ross; Betty Prine; Mohamad Shebley; Megan McNamee; Thalia Farazi; Su Young Kim; Maria Verdugo; Leanne Lash-Fleming; C Michel Zwaan; Josef Vormoor
Journal:  Future Oncol       Date:  2018-03-29       Impact factor: 3.404

4.  Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study.

Authors:  Max S Topp; Nicola Gökbuget; Anthony S Stein; Gerhard Zugmaier; Susan O'Brien; Ralf C Bargou; Hervé Dombret; Adele K Fielding; Leonard Heffner; Richard A Larson; Svenja Neumann; Robin Foà; Mark Litzow; Josep-Maria Ribera; Alessandro Rambaldi; Gary Schiller; Monika Brüggemann; Heinz A Horst; Chris Holland; Catherine Jia; Tapan Maniar; Birgit Huber; Dirk Nagorsen; Stephen J Forman; Hagop M Kantarjian
Journal:  Lancet Oncol       Date:  2014-12-16       Impact factor: 41.316

5.  Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia.

Authors:  Arend von Stackelberg; Franco Locatelli; Gerhard Zugmaier; Rupert Handgretinger; Tanya M Trippett; Carmelo Rizzari; Peter Bader; Maureen M O'Brien; Benoît Brethon; Deepa Bhojwani; Paul Gerhardt Schlegel; Arndt Borkhardt; Susan R Rheingold; Todd Michael Cooper; Christian M Zwaan; Phillip Barnette; Chiara Messina; Gérard Michel; Steven G DuBois; Kuolung Hu; Min Zhu; James A Whitlock; Lia Gore
Journal:  J Clin Oncol       Date:  2016-10-31       Impact factor: 44.544

6.  Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy.

Authors:  David T Teachey; Susan R Rheingold; Shannon L Maude; Gerhard Zugmaier; David M Barrett; Alix E Seif; Kim E Nichols; Erica K Suppa; Michael Kalos; Robert A Berg; Julie C Fitzgerald; Richard Aplenc; Lia Gore; Stephan A Grupp
Journal:  Blood       Date:  2013-05-15       Impact factor: 22.113

7.  Survival after blinatumomab treatment in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

Authors:  Lia Gore; Franco Locatelli; Gerhard Zugmaier; Rupert Handgretinger; Maureen M O'Brien; Peter Bader; Deepa Bhojwani; Paul-Gerhardt Schlegel; Catherine A Tuglus; Arend von Stackelberg
Journal:  Blood Cancer J       Date:  2018-08-22       Impact factor: 11.037

8.  t(17;19) in Children with Acute Lymphocytic Leukemia: A Report of 3 Cases and a Review of the Literature.

Authors:  Katherine A Minson; Pinki Prasad; Susan Vear; Scott Borinstein; Richard Ho; Jennifer Domm; Haydar Frangoul
Journal:  Case Rep Hematol       Date:  2013-01-03

Review 9.  Redirecting T cells to hematological malignancies with bispecific antibodies.

Authors:  Mireya Paulina Velasquez; Challice L Bonifant; Stephen Gottschalk
Journal:  Blood       Date:  2017-11-08       Impact factor: 25.476

10.  Genomics and drug profiling of fatal TCF3-HLF-positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options.

Authors:  Ute Fischer; Michael Forster; Anna Rinaldi; Thomas Risch; Stéphanie Sungalee; Hans-Jörg Warnatz; Beat Bornhauser; Michael Gombert; Christina Kratsch; Adrian M Stütz; Marc Sultan; Joelle Tchinda; Catherine L Worth; Vyacheslav Amstislavskiy; Nandini Badarinarayan; André Baruchel; Thies Bartram; Giuseppe Basso; Cengiz Canpolat; Gunnar Cario; Hélène Cavé; Dardane Dakaj; Mauro Delorenzi; Maria Pamela Dobay; Cornelia Eckert; Eva Ellinghaus; Sabrina Eugster; Viktoras Frismantas; Sebastian Ginzel; Oskar A Haas; Olaf Heidenreich; Georg Hemmrich-Stanisak; Kebria Hezaveh; Jessica I Höll; Sabine Hornhardt; Peter Husemann; Priyadarshini Kachroo; Christian P Kratz; Geertruy Te Kronnie; Blerim Marovca; Felix Niggli; Alice C McHardy; Anthony V Moorman; Renate Panzer-Grümayer; Britt S Petersen; Benjamin Raeder; Meryem Ralser; Philip Rosenstiel; Daniel Schäfer; Martin Schrappe; Stefan Schreiber; Moritz Schütte; Björn Stade; Ralf Thiele; Nicolas von der Weid; Ajay Vora; Marketa Zaliova; Langhui Zhang; Thomas Zichner; Martin Zimmermann; Hans Lehrach; Arndt Borkhardt; Jean-Pierre Bourquin; Andre Franke; Jan O Korbel; Martin Stanulla; Marie-Laure Yaspo
Journal:  Nat Genet       Date:  2015-07-27       Impact factor: 38.330

View more
  10 in total

1.  Effect of Blinatumomab vs Chemotherapy on Event-Free Survival Among Children With High-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.

Authors:  Franco Locatelli; Gerhard Zugmaier; Carmelo Rizzari; Joan D Morris; Bernd Gruhn; Thomas Klingebiel; Rosanna Parasole; Christin Linderkamp; Christian Flotho; Arnaud Petit; Concetta Micalizzi; Noemi Mergen; Abeera Mohammad; William N Kormany; Cornelia Eckert; Anja Möricke; Mary Sartor; Ondrej Hrusak; Christina Peters; Vaskar Saha; Luciana Vinti; Arend von Stackelberg
Journal:  JAMA       Date:  2021-03-02       Impact factor: 56.272

Review 2.  Advances in the Diagnosis and Treatment of Pediatric Acute Lymphoblastic Leukemia.

Authors:  Hiroto Inaba; Ching-Hon Pui
Journal:  J Clin Med       Date:  2021-04-29       Impact factor: 4.241

Review 3.  Immunotherapy of Acute Lymphoblastic Leukemia and Lymphoma With T Cell-Redirected Bispecific Antibodies.

Authors:  Federico Lussana; Giuseppe Gritti; Alessandro Rambaldi
Journal:  J Clin Oncol       Date:  2021-01-12       Impact factor: 44.544

4.  Synergistic activity of combined inhibition of anti-apoptotic molecules in B-cell precursor ALL.

Authors:  Felix Seyfried; Felix Uli Stirnweiß; Alexandra Niedermayer; Stefanie Enzenmüller; Rebecca Louise Hörl; Vera Münch; Stefan Köhrer; Klaus-Michael Debatin; Lüder Hinrich Meyer
Journal:  Leukemia       Date:  2022-01-14       Impact factor: 11.528

5.  Blinatumomab in pediatric relapsed/refractory B-cell acute lymphoblastic leukemia: RIALTO expanded access study final analysis.

Authors:  Franco Locatelli; Gerhard Zugmaier; Noemi Mergen; Peter Bader; Sima Jeha; Paul-Gerhardt Schlegel; Jean-Pierre Bourquin; Rupert Handgretinger; Benoit Brethon; Claudia Rössig; William N Kormany; Puneeth Viswagnachar; Christiane Chen-Santel
Journal:  Blood Adv       Date:  2022-02-08

6.  TCF3-HLF-Positive Acute Lymphoblastic Leukemia Resembling Burkitt Leukemia: Cell Morphologic and Immunophenotypic Findings.

Authors:  Meng-Ju Li; Chih-Hsiang Yu; Shu-Wei Chou; Ying-Hui Su; Kuang-Wen Liao; Hsiu-Hao Chang; Yung-Li Yang
Journal:  JCO Precis Oncol       Date:  2022-08

7.  Epigenetic Modification of Death Receptor Genes for TRAIL and TRAIL Resistance in Childhood B-Cell Precursor Acute Lymphoblastic Leukemia.

Authors:  Atsushi Watanabe; Kunio Miyake; Koshi Akahane; Kumiko Goi; Keiko Kagami; Hideo Yagita; Takeshi Inukai
Journal:  Genes (Basel)       Date:  2021-06-05       Impact factor: 4.096

Review 8.  Concepts in immuno-oncology: tackling B cell malignancies with CD19-directed bispecific T cell engager therapies.

Authors:  Andreas Viardot; Franco Locatelli; Julia Stieglmaier; Faraz Zaman; Elias Jabbour
Journal:  Ann Hematol       Date:  2020-08-27       Impact factor: 3.673

9.  Comprehensive chromosomal aberrations in a case of a patient with TCF3-HLF-positive BCP-ALL.

Authors:  Monika Lejman; Monika Włodarczyk; Joanna Zawitkowska; Jerzy R Kowalczyk
Journal:  BMC Med Genomics       Date:  2020-04-03       Impact factor: 3.063

10.  Aurora A kinase as a target for therapy in TCF3-HLF rearranged acute lymphoblastic leukemia.

Authors:  Jessica Leonard; Joelle Sj Wolf; Michelle Degnin; Christopher A Eide; Dorian LaTocha; Kyle Lenz; Beth Wilmot; Charles G Mullighan; Mignon Loh; Stephen P Hunger; Brian J Druker; Marc M Loriaux; Jeffrey W Tyner; Bill H Chang
Journal:  Haematologica       Date:  2021-11-01       Impact factor: 9.941

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.